Docetaxel Market Is Growing At A Significant Growth Rate During The Forecast Period Of 2019-2026


(MENAFN- Straits Research) Docetaxel injection is either used alone or in combination with other medications to treat certain types of lung, breast, stomach, prostate cancers. Actavis Pharma Company, Sun Pharma Globa, Pfizer Laboratories Div Pfizer Inc., genus Pharmaceuticals, LLC, and Mylan Institutional LLC are some of the other players offering different concentration of docetaxel intravenous formulation.
Various key players are focusing on the manufacturing of combined drugs with low toxicity, for example, Beta Drugs Limited offers different combination of Docetaxel injections. Drastic change in lifestyle, and eating habits is further increasing the prevalence of cancer across the glove. For instance, in 2018, around 17 million new incidences of cancer were diagnosed worldwide, CDC. As per the estimation of Cancer Research U.K., cancer is the second leading cause of death globally, accounting around 9.6 million deaths in 2018.
Increasing Number of Cancer Hospital to Dominate the Docetaxel Market
On the basis of end users, the market is segmented into hospital & chemotherapy centers, cancer research centers, and ambulatory surgery centers.
Hospital and chemotherapy centers is expected to hold a major market share during the forecast period 2019-2026. This can be attributed to the large number of patient visits for the treatment of various diseases. Rising number of hospital and chemotherapy centers across the globe is the major factor driving the market growth. For instance, in the U.S., there are around 5,000 hospitals, and more than 30,000 physicians work on cancer, Becker's Healthcare. Whereas, in France, there are around 18 cancer centers, and 20 hospitals. Moreover, 120,000 cancer patients are hospitalized every year. Furthermore, increasing number of different cancer hospitals across the globe is expected to influencing demand for docetaxel market. For instance, as per estimation, National Federation of French Cancer Centres, around 18 Cancer Centers and 20 hospitals cancer across the France.

Got questions about your regional growth of
Docetaxel Market?
Just drop us a line or call on +1 646 480 7505


Asia Pacific is Witnessing Rapid Demand for Docetaxel owing to High Prevalence of Lung Cancer
Asia Pacific is expected to be the fastest growing region for the docetaxel market on account of growing number of cancer patients in the region. In China, the chemical industry is experiencing a significant growth, which has improved the country's annual growth rate by 1.6%. According to the estimation of National Cancer Center, over 781,000 patients are diagnosed with lung cancer every years in china. Whereas, in Japan, Japanese men smoke more on average compared to the U.S., which is further increasing the prevalence of cancer in the country. For instance, more than 1.6 million people are dying every year due to lung cancer, International Association for the Study of Lung Cancer. Moreover, advanced hospital infrastructure and chemotherapy centers for the treatment of cancer in the region is expected to drive the market growth. Moreover, presence of various government reimbursement for cancer treatment is expected to drive the market growth. For instance, the Ministry of Health & Family Welfare provides Health Minister's Cancer Patient Fund (HMCPF) under Rashtriya Arogya Nidhi.
LAMEA is anticipated to account for the least market share due to poor healthcare infrastructure and low income of the people in Africa. Besides, limited government support for cancer treatment is restraining the market growth in the region. However, significant improvements in the healthcare facilities in Argentina and Brazil are anticipated to flourish the market growth to some extent. In the Middle East, prostate cancer care is highly variable, and access to specialist multidisciplinary management for the treatment of cancer.
Key Players
Some of the key players in the global docetaxel market are Sanofi (France), Pfizer (U. S.), Dr. Reddy's Laboratories (India), Sandoz (Germany), Actavis (U.S.), Sun pharma (India), Beijing Union Pharmaceutical Factory (China), and Accord Healthcare (U. K.)
Docetaxel Market Segmentation
By Type

Peripheral Neuropathy
Entrapment Neuropathy
Post Traumatic Neuropathy
Phantom Limb Pain
Post Herpetic Neuralgia (PHN)
Trigeminal Neuralgia
Others

By Diagnosis and Treatment

Imaging, blood tests
physical examination
Medication
Multimodal therapy
Others

Distribution Channel

Online Pharmacies,
Retail Pharmacies
Drug Stores
Others

By End-User

Hospitals
Clinics
Research Organizations
Others

By Regions covered
America
North America

U.S.
Canada
Mexico

South America
Europe
Western Europe

Germany
France
U.K
Italy
Spain
Rest of Western Europe

Eastern Europe
Asia Pacific

China
India
Japan
South Korea
Australia
Rest of Asia Pacific

The Middle East & Africa
The Middle East

Saudi Arabia
UAE
Qatar
Rest of the Middle East

Africa

" Crucial Insights The Report Provides:"
* Known and Unknown Adjacencies Influencing the Growth of Market
* Explorable Revenue Sources
* Customer Behaviour Analysis
* Target Partners
* Customized Geographical Data Based on Customers as well as Competitors
* Analysis of Market Size and CAGR between the Forecast Periods

MENAFN11072024004597010339ID1108430467


Straits Research

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.